Benefit–Risk Assessment of Vedolizumab in the Treatment of...

  • Main
  • 2019 / 3
  • Benefit–Risk Assessment of Vedolizumab in the Treatment of...
Drug Safety 2019 / 3

Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

Battat, Robert, Ma, Christopher, Jairath, Vipul, Khanna, Reena, Feagan, Brian G.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Drug Safety
DOI:
10.1007/s40264-018-00783-1
Date:
March, 2019
File:
PDF, 895 KB
2019
Conversion to is in progress
Conversion to is failed